查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837112

經導管栓塞和封堵裝置市場（按產品類型、材料、技術、應用和最終用戶分類）—2025-2032 年全球預測

Transcatheter Embolization & Occlusion Device Market by Product Type, Material, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，經導管栓塞和封堵裝置市場規模將達到 160.3 億美元，複合年成長率為 13.19%。

主要市場統計數據
基準年2024年 59.4億美元
預計2025年 67.3億美元
預測年份：2032年 160.3億美元
複合年成長率（%） 13.19%

經導管栓塞和封堵裝置的策略性引入是微創血管治療發展的關鍵驅動力

在血管微創治療日益普及的背景下，經導管栓塞和封堵裝置已成為融合先進材料科學和精準輸送系統的基礎工具。這些裝置旨在阻斷各種臨床適應症中的病理性血流，並與介入放射學、血管外科和血管內神經外科工作流程交叉。這源自於臨床上對兼具療效、精準輸送和可預測生物相容性的治療方案日益成長的需求。隨著臨床醫生越來越重視門診病人路徑和縮短手術時間，裝置設計人員正在透過創新來應對這項挑戰，以簡化操作、增強影像下的可視性並改善部署過程中的控制。

器械外形規格的不斷演變，使其治療範圍從止血和子宮肌瘤栓塞等傳統應用擴展到肝臟、周邊血管和神經血管介入治療。同時，手術團隊正在整合微導管技術與混合輸送策略，以適應複雜的解剖結構並實現持久的閉塞。監管機構持續改善微創解決方案的路徑，鼓勵製造商兼顧臨床證據產生和上市後監管。這些因素共同再形成了臨床演算法和商業模式，要求研發、臨床營運和市場進入職能部門之間更緊密的合作，以確保新產品能夠顯著改善患者預後並提高營運效率。

生物材料、輸送系統和手術流程的最新進展如何從根本上改變栓塞的臨床和商業策略

栓塞和阻塞設備領域正處於一場變革性變革之中，這場變革由生物材料、輸送系統和手術實踐的進步共同推動。材料科學的突破正在催生下一代液體栓塞劑和微球，它們具有更可預測的聚合性、更強的滲透性和可調的吸收特性，從而擴大了治療方案並提高了安全係數。同時，包括血管栓塞和可脫性彈簧圈在內的機械封堵技術正在不斷改進，以平衡血栓形成和血管保護，從而能夠針對各種解剖挑戰提供客製化解決方案。

微導管設計和血流導向輸送系統的同步改進降低了手術複雜性並提高了藥物部署的準確性。這些技術進步透過增強的成像和術中引導工具進一步放大，從而降低了設備移位的風險並提高了閉塞完整性。事實上，臨床醫生正在採用多模態策略——跨平台結合設備和材料——以在複雜病例中取得持久的效果。從商業性，這些技術進步也在推動與醫療保健系統基於價值觀的對話，強調總治療成本、手術吞吐量和長期臨床耐用性，而不僅僅是醫療設備價格。因此，製造商正在重新調整其產品組合策略，優先考慮互通性、培訓支援以及產生能夠證明現實世界和經濟效益的證據。

全面評估不斷變化的貿易政策如何再形成栓塞設備相關人員的採購、製造決策和市場准入

近期源自美國的關稅為全球醫療設備供應鏈帶來了新的複雜性，並對製造商、經銷商和醫療保健系統產生了連鎖反應。關稅可能會改變零件採購和成品進口的成本計算，促使企業做出策略轉變，例如遷移組裝業務、尋找替代供應商以及加強垂直整合，以保持利潤率和供應的連續性。對於依賴跨境採購特殊聚合物、金屬、微導管組件和影像相容標記的公司而言，這些政策變更可能會延長前置作業時間，因為供應商會重新評估其路線和庫存政策。

累積的營運影響不僅限於單位成本。採購團隊必須調整合約條款和庫存策略，以應對關稅波動；監管和品質部門必須在製造地點或零件供應商發生變化時檢驗設備配置。由於製造商優先考慮條款較優惠的市場，臨床醫生和醫院負責人可能會經歷價格動態和分階段產品推出的變化。此外，關稅主導的供應再平衡可能會加速製造業的區域化，鼓勵企業將製造地設在更靠近終端市場的地方，以降低貿易風險。因此，策略規劃需要跨採購、監管和商業團隊的綜合情境建模，以確保持續獲得​​關鍵的栓塞和封鎖技術，並保護臨床的連續性。

可操作的細分情報，展示產品類型、材料和技術如何與臨床用例和治療環境相互作用以影響採用

詳細的細分分析揭示了不同產品類型、材料、技術、臨床應用和醫療環境之間不同的性能促進因素和採用障礙，有助於確定製造商和醫療系統的策略重點。按產品類型分類，栓塞彈簧圈（有可拆卸和可推動兩種型號）對於機械閉塞至關重要，因為放置精度至關重要；而液體栓塞劑（包括乙烯 - 乙烯醇共聚物和氰基丙烯酸正丁酯配方）則適用於複雜的血管床。微球和顆粒栓塞劑可提供校準的閉塞效果和可預測的遠端滲透；而血管栓塞則可為特定解剖結構提供快速的近端血管閉塞。每種產品類別都具有獨特的操作特性、影像視覺特性和操作員學習曲線，這些都會影響臨床路徑的採用。

材料選擇進一步區分了器械的性能，因為生物藥品通常優先考慮生物相容性和吸收動力學，而合成製劑則注重一致性和長期耐用性。技術模式—血流定向栓塞、機械閉塞和微導管輸送系統—與器械選擇相互作用，以最佳化不同適應症的手術效率和療效持久性。臨床應用範圍包括止血、肝動脈栓塞、神經血管介入、周邊血管閉塞和子宮肌瘤栓塞，其中許多應用對器械的靈活性、閉塞耐用性和栓塞顆粒行為有不同的要求。最後，最終用戶環境——門診手術中心、醫院和專科診所——會影響採購通訊協定、庫存管理和培訓投資，因此需要根據每種環境量身定做產品配置和服務模式。因此，綜合的細分洞察支持有針對性的產品開發、差異化的臨床培訓以及與特定手術流程和機構採購標準一致的價值提案。

深刻的區域觀點，重點在於突出關鍵區域之間的監管、報銷和臨床採用差異，以塑造您的策略市場方針

區域動態對臨床實務模式、報銷框架和供應鏈架構有著強大的影響，導致各主要地區的優先事項有所不同。在美洲，臨床醫生的需求通常傾向於快速手術和門診病人解決方案，強調能夠促進高效工作流程和強大培訓支援的設備。該地區的監管途徑和付款人結構迫使製造商同時證明臨床有效性和經濟價值，從而影響證據生成策略和商業性通訊。

歐洲、中東和非洲的市場環境碎片化，報銷政策、基礎設施和臨床指南各不相同。這為建立客製化產品系列和合作夥伴關係創造了機會，以滿足區域培訓需求和採購週期。在亞太地區，介入療法的快速投資和新的卓越中心正在擴大栓塞療法的臨床應用範圍。供應鏈本地化和與區域經銷商建立策略聯盟通常是加速產品可及性的優先事項，但產品調整也可能需要符合病患手術偏好和器械註冊要求。最終，每個地區在監管複雜性、成本敏感性和臨床應用速度之間都有獨特的權衡，這要求製造商制定差異化的打入市場策略，並投資於本地證據和培訓項目，以實現持續應用。

檢驗競爭動態以及產品創新、證據產生和通路策略如何決定設備製造商的市場定位

栓塞和阻塞設備領域的競爭態勢由產品創新、臨床證據、服務產品和通路關係共同驅動。主要企業透過對新一代材料、更優的輸送方式和更強大的影像相容性進行有針對性的投資，同時優先考慮臨床醫生培訓和療效追蹤，從而脫穎而出。器材製造商與學術中心和臨床網路之間的夥伴關係，對於產生高品質的真實世界證據以及與介入團隊建立長期、可信賴的關係，正變得越來越重要。

在市場進入層面，經銷商、策略夥伴和直銷模式根據治療領域和最終用戶目標，各自擁有獨特的優勢。將產品創新與全面的培訓課程和強大的上市後監測相結合的公司往往能夠提高臨床醫生的忠誠度，並推動更快的採用。此外，能夠證明與現有導管平台和成像系統互通性的公司可以減少操作流程中的摩擦，加速採用。競爭定位也取決於能否成功引導醫院和門診中心的採購偏好，並提出與臨床結果和營運效率相符的清晰價值提案。綜合考慮這些因素，敏捷的創新者和成熟的既有企業必須不斷完善其產品才能保持領先地位。

為製造商提供實用的優先建議，以協調產品創新、臨床證據和商業性執行，從而加速採用

產業領導者應採取協調產品開發、臨床證據和商業性執行的行動方案，以掌握栓塞治療的長期價值。優先考慮模組化設計並與常用微導管平台相容，以減少操作阻力，並拓展多種適應症的潛在臨床應用。投資差異化生物材料和影像標記物，以增強輸送控制和可視化。這些技術差異化可以透過結構完善的研究和註冊轉化為可證實的臨床效益。

加強與臨床中心的夥伴關係，共同開發培訓項目，以提升操作人員的熟練程度並減少治療結果的差異。同時，重新評估您的供應鏈佈局，以降低關稅波動帶來的風險，並確保關鍵零件的冗餘。擴大付款方參與度，並明確整體醫療成本效益，重點關注手術時間、併發症減少和下游資源利用率等指標。最後，透過提供靈活的合約、區域證據包和售後整合支持，根據區域和機構層面的細微差別來客製化您的商業性方案。採取這些整合措施可以幫助公司降低採用門檻，在競爭激烈的採購環境中脫穎而出，並在臨床和經濟效益方面取得可衡量的改善。

我們透明的混合方法研究途徑結合了臨床證據審查、專家訪談和交叉檢驗，以提供可靠、可行的見解

本研究整合了同行評審臨床文獻、器械監管文件、衛生當局指導文件、對介入臨床醫生和採購負責人的初步訪談以及製造商技術規範的結構化綜述，以全面了解栓塞和阻塞設備的動態。資料收集著重於可重複性和資訊來源的三角測量，將關鍵意見領袖的定性見解與從公開的監管文件和醫生主導的註冊中提取的器械性能特徵相結合。受訪者的選擇反映了不同的臨床專科、執業環境和地理區域，並捕捉了一系列操作偏好和採用考慮因素。

分析方法包括對訪談記錄進行主題編碼以識別反覆出現的障礙和促成因素，交叉比較設備功能集以評估技術差異，以及情境分析以探索供應鍊和政策主導的突發事件。所有研究結果均經過反覆同儕審查檢驗，並與臨床指南和已發表的安全報告進行交叉引用。在考慮製造商提供的聲明時，我們會將其與獨立的臨床證據和監管摘要進行摘要引用，以確保做出平衡的解讀。調查方法和資料來源刻意避免依賴任何單一來源，強調混合方法的整合，從而為研發、臨床和商業領導層提供可靠且可操作的見解。

綜合結論強調了臨床、操作和策略要點，這些要點將決定哪些技術將被廣泛採用

經導管栓塞和封堵裝置佔據臨床需求、材料創新和系統級經濟考量之間的戰略樞紐。定義該領域的技術和方法日益成熟，其臨床適用性不斷擴展，同時也給製造商帶來了越來越大的壓力，要求其在不同的醫療環境中提供可證明的價值。成功的商業化取決於能否將產品效能與部署現實（例如培訓、影像相容性和供應鏈彈性）結合。此外，貿易和政策的變化凸顯了敏捷製造和採購規劃在外部衝擊下保持設備可用性的重要性。

對於整個生態系統的相關人員來說，前進的道路是明確的：投資臨床夥伴關係以建立高品質的證據，優先考慮模組化和可互通的設備設計以減少操作摩擦，並使商業模式與當地醫療保健的實際情況保持一致。透過這樣做，公司和醫療系統可以加速安全應用，改善患者治療效果，並提高手術效率。關注這些優先事項將決定哪些創新將成為標準實踐，哪些創新仍將停留在小眾領域，從而塑造微創血管治療的未來。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 生物可吸收栓塞材料的進展改善了長期血管通暢性
  • 整合即時成像模式以增強經導管手術中的導航
  • 開發形狀記憶聚合物線圈以控制阻塞並降低遷移風險
  • 利用新型可拆卸微線圈擴展周邊血管閉塞應用
  • 開發具有持續釋放動力學的針對腫瘤血管的藥物釋放型栓塞珠
  • 低調輸送系統的興起，允許進入遠端和曲折的神經血管解剖結構
  • 栓塞治療和免疫治療藥物聯合治療的應用日益增多
  • 監管部門的核准推動了整合感測器的下一代封堵器的發展

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 經導管栓塞及封堵裝置市場（依產品類型）

  • 栓塞線圈
    • 可拆卸線圈
    • 可推線圈
  • 液態栓塞劑
    • 乙烯 - 乙烯醇共聚物
    • 氰基丙烯酸正丁酯
  • 微球
  • 顆粒栓塞劑
  • 血管栓塞

9. 經導管栓塞及封堵裝置市場（依材料）

  • 生物因素
  • 合成因子

10. 經導管栓塞及封堵裝置市場（依技術）

  • 血流導栓塞
  • 機械咬合
  • 微導管輸送系統

11. 經導管栓塞及封堵裝置市場（依應用）

  • 控制出血
  • 肝栓塞
  • 神經血管栓塞
  • 周邊血管栓塞
  • 子宮肌瘤栓塞術

12. 經導管栓塞及封堵裝置市場（依最終用戶）

  • 門診手術中心
  • 醫院
  • 專科診所

13. 經導管栓塞及封堵裝置市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 經導管栓塞及封堵裝置市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 經導管栓塞及封堵裝置市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • Johnson & Johnson
    • Cook Medical LLC
    • Merit Medical Systems, Inc.
    • Penumbra, Inc.
    • AngioDynamics, Inc.
    • WL Gore & Associates, Inc.
    • B. Braun Melsungen AG
Product Code: MRR-03168519576B

The Transcatheter Embolization & Occlusion Device Market is projected to grow by USD 16.03 billion at a CAGR of 13.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.94 billion
Estimated Year [2025] USD 6.73 billion
Forecast Year [2032] USD 16.03 billion
CAGR (%) 13.19%

A strategic introduction framing transcatheter embolization and occlusion devices as pivotal drivers of minimally invasive vascular therapy evolution

Transcatheter embolization and occlusion devices have emerged as foundational tools within the broader shift toward less invasive vascular therapies, integrating advanced materials science with precision delivery systems. These devices are engineered to occlude pathological blood flow across a diverse set of clinical indications, and they intersect with interventional radiology, vascular surgery, and endovascular neurosurgery workflows. The landscape is characterized by escalating clinical demand for options that combine efficacy, delivery accuracy, and predictable biocompatibility. As clinicians increasingly prioritize outpatient pathways and shorter procedural times, device designers are responding with innovations that streamline handling, enhance visibility under imaging, and improve controllability during deployment.

The evolution of device form factors has expanded therapeutic reach beyond traditional applications such as hemorrhage control and uterine fibroid embolization to embrace hepatic, peripheral vascular, and neurovascular interventions. Concurrently, procedural teams are integrating microcatheter technologies and hybrid delivery strategies to navigate complex anatomy and achieve durable occlusion. Regulatory authorities continue to refine pathways for minimally invasive solutions, prompting manufacturers to address both clinical evidence generation and post-market surveillance. Taken together, these forces are reshaping clinical algorithms and commercial models, demanding closer alignment among R&D, clinical affairs, and market access functions to ensure that new products deliver measurable improvements in patient outcomes and operational efficiency.

How recent advances in biomaterials, delivery systems, and procedural workflows are fundamentally reshaping clinical practice and commercial strategies in embolization

The landscape for embolization and occlusion devices is in the midst of transformative shifts driven by converging advances in biomaterials, delivery systems, and procedural practice. Material science breakthroughs are enabling next-generation liquid embolics and microspheres that offer more predictable polymerization, enhanced radiopacity, and tunable resorption profiles, thereby widening therapeutic options and improving safety margins. At the same time, mechanical occlusion technologies including vascular plugs and detachable coils are being refined to balance thrombogenicity with vessel preservation, enabling tailored solutions for diverse anatomic challenges.

Parallel improvements in microcatheter design and flow-directed delivery systems are lowering procedural complexity and increasing the precision of agent deployment. These technological gains are amplified by enhanced imaging modalities and intra-procedural guidance tools that together reduce device migration risk and improve occlusion completeness. In practice, clinicians are adopting multimodal strategies-combining devices and materials across platforms-to achieve durable outcomes in complex cases. Commercially, these technical evolutions are prompting value-based conversations with health systems that emphasize total cost of care, procedural throughput, and long-term clinical durability rather than device price alone. Consequently, manufacturers are recalibrating portfolio strategies to prioritize interoperability, training support, and evidence generation that demonstrate real-world clinical and economic benefits.

Comprehensive appraisal of how evolving trade policies are reshaping procurement, manufacturing decisions, and market access for embolization device stakeholders

Recent tariff measures originating from the United States have injected fresh complexity into global supply chains for medical devices, with cascading implications for manufacturers, distributors, and health systems. Tariffs alter the cost calculus of component sourcing and finished goods imports, which can prompt strategic shifts such as relocating assembly operations, qualifying alternative suppliers, or increasing vertical integration to preserve margin and supply continuity. For companies reliant on cross-border procurement of specialized polymers, metals, microcatheter components, and imaging-compatible markers, these policy changes can increase lead times as vendors reassess routing and inventory policies.

The cumulative operational impact extends beyond unit costs. Procurement teams are adjusting contract terms and inventory strategies to buffer against tariff volatility, while regulatory and quality functions must revalidate device configurations when manufacturing locations or component suppliers change. Clinicians and hospital purchasers may encounter altered pricing dynamics or phased product introductions as manufacturers prioritize allocations to markets with more favorable trade terms. Moreover, tariff-driven supply rebalancing can accelerate regionalization of manufacturing, encouraging companies to co-locate production nearer to end markets to reduce trade exposure. As a result, strategic planning now requires integrated scenario modeling across procurement, regulatory, and commercial teams to ensure uninterrupted access to critical embolization and occlusion technologies and to protect clinical continuity.

Actionable segmentation intelligence showing how product types, materials, and technologies interplay with clinical use cases and care settings to shape adoption

Deep segmentation analysis reveals distinct performance drivers and adoption barriers across product categories, materials, technologies, clinical applications, and care settings that determine strategic priorities for manufacturers and health systems. Within product types, embolization coils-available as detachable and pushable configurations-remain integral for targeted mechanical occlusion where placement precision is paramount, while liquid embolic agents, including ethylene vinyl alcohol copolymer and N-butyl cyanoacrylate formulations, provide conformable options for complex vascular beds. Microspheres and particulate embolic agents offer calibrated occlusion with predictable distal penetration, and vascular plugs deliver rapid proximal vessel occlusion for certain anatomies. Each product class carries unique handling characteristics, imaging visibility profiles, and operator learning curves that influence clinical pathway adoption.

Material selection further differentiates device performance, as biological agents often emphasize biocompatibility and resorption dynamics, while synthetic agents provide consistency and longer-term permanence. Technology modalities-flow-directed embolization, mechanical occlusion, and microcatheter delivery systems-interact with device choice to optimize procedural efficiency and outcome durability across indications. Clinical applications span hemorrhage control, hepatic embolization, neurovascular interventions, peripheral vascular occlusions, and uterine fibroid embolization, many of which place divergent demands on device flexibility, occlusion permanence, and embolic particle behavior. Finally, end user environments such as ambulatory surgical centers, hospitals, and specialty clinics influence purchasing protocols, inventory management, and training investments, with each setting requiring tailored product configurations and service models. Integrated segmentation insight therefore supports targeted product development, differentiated clinical training, and value propositions that align with specific procedural workflows and institutional procurement criteria.

Insightful regional perspectives highlighting how regulatory, reimbursement, and clinical adoption differences across major territories shape strategic market approaches

Regional dynamics exert a powerful influence on clinical practice patterns, reimbursement frameworks, and supply chain architectures, resulting in divergent priorities across major geographies. In the Americas, clinician demand often favors rapid procedural turnaround and outpatient-capable solutions, prompting emphasis on devices that facilitate efficient workflows and strong training support. Regulatory pathways and payer structures in this region pressure manufacturers to demonstrate both clinical efficacy and economic value, which in turn shapes evidence generation strategies and commercial messaging.

Across Europe, the Middle East & Africa, the market environment is fragmented by heterogeneous reimbursement policies, variable infrastructure, and diverse clinical guidelines. This creates opportunities for regionally adapted product portfolios and collaborative partnerships that address local training needs and procurement cycles. In Asia-Pacific, rapid investments in interventional capacity and emerging centers of excellence are expanding the clinical footprint for embolization therapies. Supply chain localization and strategic alliances with regional distributors are often prioritized to accelerate access, while product adaptations may be needed to match procedural preferences and device registration requirements. Ultimately, each region presents unique trade-offs between regulatory complexity, cost sensitivities, and clinical adoption velocities, requiring manufacturers to deploy differentiated market entry strategies and to invest in local evidence and training programs to achieve sustained uptake.

Examination of competitive dynamics and how product innovation, evidence generation, and channel strategies determine market positioning for device manufacturers

Competitive dynamics in the embolization and occlusion device arena are driven by a combination of product innovation, clinical evidence, service offerings, and channel relationships. Leading companies differentiate through targeted investments in next-generation materials, improved delivery profiles, and enhanced imaging compatibility, while also prioritizing clinician training and outcomes tracking. Partnerships between device manufacturers and academic centers or clinical networks are increasingly important for generating high-quality real-world evidence and building long-term credibility with interventional teams.

At the go-to-market level, distributors, strategic alliances, and direct sales models each offer distinct advantages depending on the therapeutic area and end user target. Companies that pair product innovation with comprehensive training curricula and robust post-market surveillance tend to foster stronger clinician loyalty and faster uptake. Moreover, firms that can demonstrate interoperability with existing catheter platforms and imaging systems reduce procedural friction and accelerate adoption. Competitive positioning also depends on the ability to navigate procurement preferences in hospitals and ambulatory centers, and to present clear value propositions that align with both clinical outcomes and operational efficiencies. Collectively, these factors create a landscape where nimble innovators and established incumbents must continually refine their offerings to sustain leadership.

Practical and prioritized recommendations for manufacturers to align product innovation, clinical evidence, and commercial execution to accelerate adoption

Industry leaders should pursue a coordinated set of actions that align product development, clinical evidence objectives, and commercial execution to capture long-term value in embolization therapies. Prioritize modular design and compatibility with commonly used microcatheter platforms to reduce procedural friction and to broaden clinical applicability across multiple indications. Invest in differentiated biomaterials and imaging markers that enhance delivery control and visualization; these technical distinctions can be translated into demonstrable clinical benefits through well-structured studies and registries.

Strengthen partnerships with clinical centers to co-develop training programs that accelerate operator proficiency and reduce variability in outcomes. Simultaneously, reassess supply chain footprints to mitigate exposure to tariff-driven disruptions and to ensure redundancy for critical components. Expand payer engagement to articulate total cost of care benefits, focusing on metrics such as procedural time, complication reduction, and downstream resource utilization. Finally, tailor commercial approaches to regional and facility-level nuances by offering flexible contracting, local evidence packages, and integrated post-sales support. By taking these integrated steps, companies can reduce adoption barriers, differentiate in competitive procurement environments, and demonstrate measurable improvements in both clinical and economic outcomes.

Transparent mixed-methods research approach combining clinical evidence review, expert interviews, and cross-validation to ensure robust actionable insights

This research synthesizes peer-reviewed clinical literature, device regulatory filings, guidance documents from health authorities, primary interviews with interventional clinicians and procurement leaders, and a structured review of manufacturer technical specifications to create a comprehensive understanding of embolization and occlusion device dynamics. Data collection emphasized reproducibility and source triangulation, combining qualitative insights from key opinion leaders with device performance characteristics extracted from publicly available regulatory submissions and physician-led registries. Interview subjects were selected to reflect a diversity of clinical specialties, practice settings, and geographic regions to capture the breadth of procedural preferences and adoption considerations.

Analytical methods included thematic coding of interview transcripts to identify recurring barriers and enablers, cross-comparison of device feature sets to assess technological differentiation, and scenario analysis to explore supply chain and policy-driven contingencies. All findings were validated through iterative expert review and reconciled against clinical guidelines and published safety reports. Where manufacturer-provided claims were considered, they were corroborated with independent clinical evidence and regulatory summaries to ensure balanced interpretation. The methodology intentionally avoided reliance on single-source commercial data, favoring mixed-methods synthesis to provide robust, actionable insights for R&D, clinical affairs, and commercial leadership.

Concluding synthesis emphasizing clinical, operational, and strategic imperatives that will determine which technologies achieve widespread adoption

Transcatheter embolization and occlusion devices occupy a strategic nexus of clinical need, materials innovation, and system-level economic considerations. The techniques and technologies that define this field are maturing in ways that expand clinical applicability while simultaneously increasing demands on manufacturers to deliver demonstrable value across diverse care settings. Successful commercialization will hinge on an ability to reconcile product performance with pragmatic deployment factors such as training, imaging compatibility, and supply chain resilience. Moreover, trade and policy shifts underscore the importance of agile manufacturing and procurement planning to sustain device availability in the face of external shocks.

For stakeholders across the ecosystem, the path forward is clear: invest in clinical partnerships to build high-quality evidence, prioritize modular and interoperable device designs to reduce procedural friction, and align commercial models with regional healthcare realities. By doing so, companies and health systems can accelerate safe adoption, improve patient outcomes, and enhance procedural efficiency. The collective focus on these priorities will determine which innovations translate into standard practice and which remain niche interventions, shaping the future of minimally invasive vascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in bioresorbable embolic materials improving long-term vessel patency
  • 5.2. Integration of real-time imaging modalities for enhanced navigation during transcatheter procedures
  • 5.3. Development of shape-memory polymer coils offering controlled occlusion and reduced migration risk
  • 5.4. Expansion of peripheral vascular occlusion applications with novel detachable microcoils
  • 5.5. Emergence of drug-eluting embolic beads targeting tumor vasculature with sustained release kinetics
  • 5.6. Rise of low-profile delivery systems enabling access to distal and tortuous neurovascular anatomy
  • 5.7. Increased adoption of combination therapies coupling embolization with immunotherapy agents
  • 5.8. Regulatory approvals driving growth of next-generation occlusion devices with integrated sensors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Embolization & Occlusion Device Market, by Product Type

  • 8.1. Embolization Coils
    • 8.1.1. Detachable Coils
    • 8.1.2. Pushable Coils
  • 8.2. Liquid Embolic Agents
    • 8.2.1. Ethylene Vinyl Alcohol Copolymer
    • 8.2.2. N-Butyl Cyanoacrylate
  • 8.3. Microspheres
  • 8.4. Particulate Embolic Agents
  • 8.5. Vascular Plugs

9. Transcatheter Embolization & Occlusion Device Market, by Material

  • 9.1. Biological Agents
  • 9.2. Synthetic Agents

10. Transcatheter Embolization & Occlusion Device Market, by Technology

  • 10.1. Flow Directed Embolization
  • 10.2. Mechanical Occlusion
  • 10.3. Microcatheter Delivery Systems

11. Transcatheter Embolization & Occlusion Device Market, by Application

  • 11.1. Hemorrhage Control
  • 11.2. Hepatic Embolization
  • 11.3. Neurovascular Embolization
  • 11.4. Peripheral Vascular Embolization
  • 11.5. Uterine Fibroid Embolization

12. Transcatheter Embolization & Occlusion Device Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Transcatheter Embolization & Occlusion Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transcatheter Embolization & Occlusion Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transcatheter Embolization & Occlusion Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Boston Scientific Corporation
    • 16.3.2. Medtronic plc
    • 16.3.3. Terumo Corporation
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Cook Medical LLC
    • 16.3.6. Merit Medical Systems, Inc.
    • 16.3.7. Penumbra, Inc.
    • 16.3.8. AngioDynamics, Inc.
    • 16.3.9. W. L. Gore & Associates, Inc.
    • 16.3.10. B. Braun Melsungen AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PR